{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Number of patients with organ response based on standard criteria included in protocol.\n\nCardiac response is defined as: NT-proBNP response (\\>30% and \\>300 ng/L decrease in patients with a baseline NT-proBNP \\>650 ng/L; and/or NYHA class response (\\> two-class decrease if baseline NYHA class 3 or 4)\n\nRenal response is defined as: Decrease in proteinuria by \\> 30% or below 0.5 g/24 h without renal progression. Serum creatinine and creatinine clearance must not worsen by 25% over baseline","groups":[{"description":"Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month for up to 24 total cycles.\n\nDaratumumab: Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression, inability to tolerate, or 24 cycles completed.","id":"OG000","title":"Daratumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"19 evaluable patients with cardiac and/or renal involvement.","reportingStatus":"POSTED","timeFrame":"3 months","title":"Assess Organ Responses Based on Standard Criteria Included in Protocol","type":"SECONDARY","unitOfMeasure":"Participants"}